FindTrial
Sign In

A medical records based retrospective research for the predictive model for EGFR mutation status in patients with lung adenocarcinoma

The predictive model for EGFR mutation status in patients with lung adenocarcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044954
Enrollment
Unknown
Registered
2021-04-03
Start date
2021-04-06
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

development group:NA
validation group:NA

Sponsors

Shanghai Jiaotong University School of Medicine, Renji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.The pathology is clearly an adult patient with primary lung adenocarcinoma (age greater than 18 years old), with clinical data, including: age, gender, smoking history, TNM staging, tumor indicators; 2.There is a thin-slice chest CT examination before the initial treatment (within one month before the initial treatment); 3.Have clear pathological data of lung adenocarcinoma; 4.Have EGFR gene test results.

Exclusion criteria

Exclusion criteria: Suffering from squamous cell carcinoma, adenosquamous carcinoma, large cell lung cancer, undifferentiated lung cancer, large cell lung cancer.

Design outcomes

Primary

MeasureTime frame
EGFR gene mutation;—

Countries

China

Contacts

Public ContactZou Jing

Shanghai Jiaotong University School of medicine, Renji Hospital

drzouj@163.com+86 13818108334

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026